Amorfix turnaround builds broad pipeline

What a difference a year makes. In 2010, Amorfix Life Sciences (TSX:AMF) pulled the plug on its lead blood test to detect the human variant of Creutzfeldt-Jakob disease, thereby halving its stock price and prompting a management shakeup. Today, Amorfix has built an innovative, early-stage product pipeline, including diagnostics and therapeutics for neurodegenerative diseases and [...]

Helix BioPharma gets request for shareholders’ meeting

Directors of Helix BioPharma (TSX, AMEX, FSE:HBP) have received a shareholder requisition to call a meeting of shareholders to elect directors and set the number of directors to be elected at the meeting at seven. The shareholders making the requisition, who were not identified, have proposed a slate which includes three new directors and four [...]

Helix to start on Amex Wednesday

Helix BioPharma (TSX,FSE:HBP; OTCQX:HXBPF) is expected to begin trading on the NYSE Amex exchange at the opening Wednesday under the symbol HBP, delisting its shares from the OTCCQ at the same time. The listings on the Toronto and Frankfurt stock exchanges are unaffected. “We believe that listing on the NYSE Amex stock exchange will prove [...]

Helix closes private placement with Polish investor

Helix BioPharma (TSX,FSE:HBP; OTCQX:HXBPF) has closed a private placement of 4.53 million units at a price of $2.43 a unit with Polish investor Zbigniew Lobacz, who acquired the units for investments purposes. Net proceeds of about $9.5 million will be used for working capital, primarily to support the company’s clinical trials. Each unit consists of one [...]

Helix cream has no statistical significance for AGW

Helix BioPharma (TSX,FSE:HBP; OTCQX:HXBPF) has released results of a Phase 2 clinical trial of its topical interferon Alpha-2b cream for the treatment of ano-genital warts, which showed no statistically significant treatment effects between the treatment and the placebo groups. Topical interferon Alpha-2b was very well tolerated and there were no treatment-related serious adverse events, which is consistent [...]

Helix BioPharma has positive interim Phase 2 results

The first 10 patients enrolled in Helix BioPharma’s Phase 2 pharmacokinetic study of topical interferon Alpha-2b, in patients with low-grade cervical lesions, have completed the pharmacokinetic primary end point analyses with positive findings. “Given the uniformity of the primary endpoint findings to-date, we intend to conclude patient recruitment for this study once a total of [...]